Tracking CIDP treatment with a smartwatch
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests whether a smartwatch can help monitor how well subcutaneous immunoglobulin (fSCIG) works for people with CIDP who recently switched from IVIG or plan to switch. It aims to make treatment tracking easier and more convenient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have typical or possible typical CIDP (based on standard medical criteria).
- You are at least 18 years old.
- You are able to use a smartwatch (the study team will decide if you can).
- You have recently switched from IVIG to fSCIG (in the last 6 months) or plan to switch during the study.
- Your previous IVIG treatment was stable (confirmed by your doctor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving immune globulin under the skin (SCIG) can help people with newly diagnosed CIDP. It may help improve muscle strength and nerve symptoms while avoiding the need for earlier IVIG/SCIG treatment.
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
This study looks at people with CIDP who are stable on IVIg treatment to see if we can predict when they might get worse if their treatment is adjusted. It aims to make treatment management easier and more personalized.
This study tests different ways of monitoring people with relapsing-remitting MS who are reducing or stopping their medication. It aims to find the safest follow-up approach and may help guide future treatment decisions for those with stable disease.
This Phase 1 study compares IVIG given through an IV versus SCIG given under the skin, for people with CIDP. It aims to find the right weekly SCIG dose based on your current IVIG dose, which could make treatment more convenient.
This trial tests whether a blood-filtering treatment called immunoadsorption can help people with CIDP. It is for adults who are already receiving or starting IVIg or MP therapy.
Hear when a new CIDP - Chronic Inflammatory Demyelinating Polyneuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.